|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.00 INR | -0.51% |
|
-5.71% | -30.76% |
Company Valuation: Pharmaids Pharmaceuticals Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 46.4 | 115.3 | 129 | 488.8 | 1,834 | 2,422 |
| Change | - | 148.44% | 11.9% | 278.93% | 275.2% | 32.06% |
| Enterprise Value (EV) 1 | 46.18 | 113.3 | 124.9 | 328.2 | 1,871 | 2,790 |
| Change | - | 145.28% | 10.28% | 162.73% | 470.15% | 49.11% |
| P/E | 150x | 124x | 89.4x | -3.72x | -14.8x | -22.5x |
| PBR | 0.55x | 1.35x | 1.49x | 2.09x | 2.55x | 4.08x |
| PEG | - | 1x | 1.6x | 0x | 0.4x | 1.7x |
| Capitalization / Revenue | - | 1,348,141x | 3,274,561x | - | 12,135,482x | 12,411,040x |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -13.8x | 106x | 91.1x | -3.45x | -13.8x | -21.8x |
| EV / EBIT | -12.3x | 182x | 97.7x | -3.44x | -12.7x | -18.5x |
| EV / FCF | 1.33x | 32x | 37x | -4.61x | -6.08x | -15.2x |
| FCF Yield | 75.5% | 3.13% | 2.71% | -21.7% | -16.5% | -6.6% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | 0.03 | 0.09 | 0.14 | -5.86 | -3.507 | -3.056 |
| Distribution rate | - | - | - | - | - | - |
| Net sales | - | 85.51 | 39.39 | - | 151.1 | 195.1 |
| EBITDA 1 | -3.355 | 1.069 | 1.371 | -95.2 | -135.5 | -128 |
| EBIT 1 | -3.743 | 0.6209 | 1.279 | -95.37 | -146.9 | -151.1 |
| Net income 1 | 0.3353 | 0.9331 | 1.451 | -75.56 | -79.68 | -107.8 |
| Net Debt 1 | -0.2178 | -2.003 | -4.074 | -160.6 | 37.29 | 368.3 |
| Reference price 2 | 4.50 | 11.18 | 12.51 | 21.81 | 52.00 | 68.67 |
| Nbr of stocks (in thousands) | 10,311 | 10,311 | 10,311 | 22,411 | 35,268 | 35,268 |
| Announcement Date | 8/21/20 | 8/30/21 | 7/23/22 | 8/31/23 | 9/3/24 | 8/29/25 |
1INR in Million2INR
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| - | - | - | - | 12.09M | ||
| 35.04x | 12.53x | 26.21x | 0.57% | 1,051B | ||
| 27.19x | 6.2x | 16.98x | 2.12% | 609B | ||
| 33.15x | 7.52x | 15.43x | 2.7% | 450B | ||
| 17.85x | 4.43x | 10.91x | 3% | 330B | ||
| 21.66x | 5.55x | 13.44x | 2.84% | 284B | ||
| 21.16x | 4.46x | 12.34x | 1.97% | 263B | ||
| 14.45x | 5.41x | 11.15x | 3.44% | 223B | ||
| 24.02x | 6.35x | 11.22x | 2.75% | 198B | ||
| -48.37x | 5.78x | 31.95x | 2.42% | 167B | ||
| Average | 16.24x | 6.47x | 16.62x | 2.42% | 357.51B | |
| Weighted average by Cap. | 24.01x | 7.82x | 18.33x | 2% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PHARMAID Stock
- Valuation Pharmaids Pharmaceuticals Limited
Select your edition
All financial news and data tailored to specific country editions
















